Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPIRE 2: inhaled ciprofloxacin DPI intermittent regimens in non-cystic fibrosis bronchiectasis
NL-OMON41580Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Aug 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ciprofloxacin in bronchiectasis, sponsored by Bayer. Started Aug 2014; status: active, not recruiting.
02
Drugs
ciprofloxacin
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NL-OMON41580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41580.